Glucagon-Like Peptide-1 Receptor

• 

  Subject Areas on Research

  • 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. 
  • Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population". 
  • Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. 
  • Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). 
  • Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass. 
  • CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. 
  • Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. 
  • Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. 
  • Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. 
  • Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. 
  • Central Nervous System GLP-1 Receptors Regulate Islet Hormone Secretion and Glucose Homeostasis in Male Rats. 
  • Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. 
  • Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: Results From the EXSCEL Trial. 
  • DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain. 
  • Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia. 
  • Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 
  • Discordance between GLP-1R gene and protein expression in mouse pancreatic islet cells. 
  • Disruption of Glucagon-Like Peptide 1 Signaling in Sim1 Neurons Reduces Physiological and Behavioral Reactivity to Acute and Chronic Stress. 
  • Duodenal-jejunal exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 receptor-mediated mechanism. 
  • Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. 
  • Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction: Insights From the FIGHT Trial. 
  • Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. 
  • Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. 
  • Enhanced Glucose Control Following Vertical Sleeve Gastrectomy Does Not Require a β-Cell Glucagon-Like Peptide 1 Receptor. 
  • Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans. 
  • GLP-1 and energy balance: an integrated model of short-term and long-term control. 
  • GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. 
  • GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. 
  • GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats. 
  • GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs. 
  • Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population. 
  • Genetically Encoded Cholesterol-Modified Polypeptides. 
  • Give the receptor a brake: slowing gastric emptying by GLP-1. 
  • Glucagon lowers glycemia when β-cells are active. 
  • Glucagon receptor as a drug target: A witches' brew of eye of newt (peptides) and toe of frog (receptors). 
  • Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization. 
  • Glucagon-like peptide 1 (GLP-1). 
  • Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic. 
  • Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. 
  • Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. 
  • Gut peptides in the treatment of diabetes mellitus. 
  • High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. 
  • Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. 
  • Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. 
  • Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. 
  • Interaction of GLP-1 and Ghrelin on Glucose Tolerance in Healthy Humans. 
  • Is GLP-1 a hormone: Whether and When? 
  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. 
  • Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. 
  • Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect. 
  • New antihyperglycemic medications with cardiovascular protection for patients with diabetes: What do surgeons need to know? 
  • Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. 
  • Oral L-arginine stimulates GLP-1 secretion to improve glucose tolerance in male mice. 
  • Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. 
  • Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. 
  • Role of GLP-1 Receptor Agonists in Pediatric Obesity: Benefits, Risks, and Approaches to Patient Selection. 
  • Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. 
  • Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4. 
  • Targeted gene disruption in endocrine research--the case of glucagon-like peptide-1 and neuroendocrine function. 
  • Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. 
  • Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes. 
  • The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice. 
  • The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. 
  • The effects of GLP-1 infusion in the hepatic portal region on food intake. 
  • The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. 
  • The role of β cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. 
  • Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. 
  • Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 
  • Utilizing the GLP-1 signaling system to treat diabetes: sorting through the pharmacologic approaches. 
  • What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.